UA110131C2 - ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ - Google Patents

ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ

Info

Publication number
UA110131C2
UA110131C2 UAA201312693A UAA201312693A UA110131C2 UA 110131 C2 UA110131 C2 UA 110131C2 UA A201312693 A UAA201312693 A UA A201312693A UA A201312693 A UAA201312693 A UA A201312693A UA 110131 C2 UA110131 C2 UA 110131C2
Authority
UA
Ukraine
Prior art keywords
heading
thieno
normal
pyrimidine derivatives
treat arrhythmia
Prior art date
Application number
UAA201312693A
Other languages
English (en)
Ukrainian (uk)
Inventor
Дерек Едвард Джон
Джон Форд
Original Assignee
Ксеншн Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA110131(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ксеншн Лімітед filed Critical Ксеншн Лімітед
Publication of UA110131C2 publication Critical patent/UA110131C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Данное изобретение касается соединений тиенопиримидина, которые являются ингибиторами калиевых каналов. Также описываются фармацевтические композиции, которые содержат указанные соединения, и их применение в лечении аритмии.
UAA201312693A 2011-04-01 2012-03-29 ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ UA110131C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (en) 2011-04-01 2012-03-29 Thieno [2, 3 -d] pyrimidine derivatives and their use to treat arrhythmia

Publications (1)

Publication Number Publication Date
UA110131C2 true UA110131C2 (ru) 2015-11-25

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201312693A UA110131C2 (ru) 2011-04-01 2012-03-29 ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ

Country Status (42)

Country Link
US (1) US9249155B2 (ru)
EP (1) EP2694518B1 (ru)
JP (1) JP5826374B2 (ru)
KR (1) KR20140023332A (ru)
CN (1) CN103492392B (ru)
AP (1) AP2013007198A0 (ru)
AR (1) AR088735A1 (ru)
AU (1) AU2012235882B2 (ru)
BR (1) BR112013025236A2 (ru)
CA (1) CA2831493A1 (ru)
CL (1) CL2013002789A1 (ru)
CO (1) CO6801756A2 (ru)
CR (1) CR20130488A (ru)
CU (1) CU24173B1 (ru)
CY (1) CY1117025T1 (ru)
DK (1) DK2694518T3 (ru)
EA (1) EA201301111A1 (ru)
EC (1) ECSP13012988A (ru)
ES (1) ES2558563T3 (ru)
GB (1) GB201105659D0 (ru)
GT (1) GT201300225A (ru)
HK (2) HK1193096A1 (ru)
HR (1) HRP20151340T1 (ru)
HU (1) HUE028438T2 (ru)
IL (1) IL228555A0 (ru)
MA (1) MA35064B1 (ru)
ME (1) ME02314B (ru)
MX (1) MX335937B (ru)
NI (1) NI201300100A (ru)
PE (1) PE20141021A1 (ru)
PL (1) PL2694518T3 (ru)
PT (1) PT2694518E (ru)
RS (1) RS54458B1 (ru)
RU (1) RU2013148627A (ru)
SG (1) SG193578A1 (ru)
SI (1) SI2694518T1 (ru)
SM (1) SMT201500322B (ru)
TN (1) TN2013000377A1 (ru)
TW (1) TWI516265B (ru)
UA (1) UA110131C2 (ru)
WO (1) WO2012131379A1 (ru)
ZA (1) ZA201307085B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078957A1 (en) * 2012-11-20 2014-05-30 The Royal Institution For The Advancement Of Learning/Mcgill University Thienopyrimidine inhibitors of farnesyl and/or geranylgeranyl pyrophosphate synthase
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
WO2018237084A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC COMPOUNDS INTERACTING WITH RAS SUPERFAMIL FOR USE IN THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES AND FIBROTIC DISEASES

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
EP0846119B1 (en) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use as endothelin antagonists
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
EP0934296B1 (en) 1996-07-26 2003-06-04 Nissan Chemical Industries, Limited Chroman derivatives
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
EP1082315A1 (en) 1998-06-05 2001-03-14 Icagen, Inc. Potassium channel inhibitors
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1212314B1 (en) 1999-09-17 2005-11-30 Nissan Chemical Industries, Ltd. Benzopyran derivative
US6555574B1 (en) 1999-09-24 2003-04-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
EP1218367A1 (en) 1999-10-05 2002-07-03 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2393756A1 (en) 1999-12-21 2001-06-28 Aimee D. Reed Potassium channel inhibitors
CA2421819C (en) 2000-09-20 2010-03-09 Merck & Co., Inc. Isoquinolinone potassium channel inhibitors
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
BR0206853A (pt) 2001-02-02 2004-01-13 Merck Patent Ges Mit Beschroen Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE60206505T2 (de) 2001-06-25 2006-07-06 Nissan Chemical Industries, Ltd. Substituierte benzopyranderivate gegen arrhytmie
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
EP1641803B3 (en) * 2003-06-11 2010-12-08 Xention Limited Thienopyrimidine derivatives as potassium channel inhibitors
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
WO2005066182A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
AU2005260077A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
EP2043654A2 (en) 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thienopyrimidines useful as modulators of ion channels
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
MX335937B (es) 2016-01-04
NI201300100A (es) 2014-01-07
GT201300225A (es) 2014-12-30
EP2694518B1 (en) 2015-10-07
US20140206703A1 (en) 2014-07-24
CN103492392A (zh) 2014-01-01
CY1117025T1 (el) 2017-04-05
SG193578A1 (en) 2013-10-30
ECSP13012988A (es) 2013-12-31
PE20141021A1 (es) 2014-08-30
RS54458B1 (en) 2016-06-30
BR112013025236A2 (pt) 2019-09-24
GB201105659D0 (en) 2011-05-18
CO6801756A2 (es) 2013-11-29
IL228555A0 (en) 2013-12-31
PT2694518E (pt) 2016-02-05
ME02314B (me) 2016-06-20
PL2694518T3 (pl) 2016-03-31
SI2694518T1 (sl) 2016-02-29
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
HK1193806A1 (zh) 2014-10-03
CA2831493A1 (en) 2012-10-04
JP5826374B2 (ja) 2015-12-02
KR20140023332A (ko) 2014-02-26
HRP20151340T1 (hr) 2016-02-26
CU24173B1 (es) 2016-04-25
TW201244720A (en) 2012-11-16
ZA201307085B (en) 2015-04-29
CN103492392B (zh) 2015-11-25
NZ615621A (en) 2015-01-30
HUE028438T2 (en) 2017-02-28
CL2013002789A1 (es) 2014-07-18
WO2012131379A1 (en) 2012-10-04
US9249155B2 (en) 2016-02-02
SMT201500322B (it) 2016-02-25
DK2694518T3 (en) 2015-11-09
MA35064B1 (fr) 2014-04-03
TWI516265B (zh) 2016-01-11
EA201301111A1 (ru) 2014-02-28
HK1193096A1 (zh) 2014-09-12
EP2694518A1 (en) 2014-02-12
MX2013011301A (es) 2014-04-16
ES2558563T3 (es) 2016-02-05
AR088735A1 (es) 2014-07-02
AU2012235882A1 (en) 2013-05-02
JP2014509637A (ja) 2014-04-21
CR20130488A (es) 2013-12-06
AP2013007198A0 (en) 2013-10-31
CU20130124A7 (es) 2014-01-29
AU2012235882B2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
PH12019502809A1 (en) Substituted tricyclic compounds as fgfr inhibitors
AU2018236800B2 (en) DNA-PK inhibitors
AU2018256591A1 (en) Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
WO2013163190A8 (en) Dna-pk inhibitors
MX363715B (es) Formas solidas de un inhbidor de cdk4/6 selectivo.
MX2014015004A (es) Inhibidores de bromodominio de benzo [c] isoxazoloazepina y sus usos.
MY177344A (en) Compounds and their methods of use
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
MX338515B (es) Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio.
MX2013001677A (es) Formulaciones estables de linaclotida.
MX350112B (es) Derivados de furo[3,2-b]- y tieno[3,2-b]piridina como inhibidores de tbk1 e ikk.
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
MX352927B (es) Derivados de 1h-pirrolo [2,3-b] piridina y su uso como inhibidores de quinasa.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2012162513A3 (en) Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
TN2013000377A1 (en) Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
WO2013155465A8 (en) Substituted xanthine derivatives
MX2013002446A (es) Derivados de tetrahidropirrolopirazina sustituidos.
PH12016502133A1 (en) Substituted tricycle compounds as fgfr inhibitors
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof